0HA3.L - Adverum Biotechnologies, Inc.
LSE - LSE Delayed Price. Currency in USD
At close: 03:45PM BST
Stock chart is not supported by your current browser
| Previous close | 1.0000 |
| Open | 0.9600 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's range | 0.9357 - 0.9700 |
| 52-week range | 0.5350 - 1.7520 |
| Volume | |
| Avg. volume | 2,047 |
| Market cap | 778,465 |
| Beta (5Y monthly) | 0.73 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.5780 |
| Earnings date | 09 Aug 2023 - 14 Aug 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
ZacksIs Adial Pharmaceuticals (ADIL) Stock Outpacing Its Medical Peers This Year?
Here is how Adial Pharmaceuticals, Inc. (ADIL) and Adverum Biotechnologies (ADVM) have performed compared to their sector so far this year.
ZacksAdverum (ADVM) Doses First Patient in the Mid-Stage wAMD Study
Adverum (ADVM) initiates dosing in the phase II LUNA study, currently investigating its lead product candidate ixoberogene soroparvovec for wet age-related macular degeneration.
ZacksAdverum (ADVM) Completes IND Amendment for Gene Therapy Study
Adverum (ADVM) completes IND amendment with the FDA for initiating the phase II LUNA study on its gene therapy candidate, ADVM-022, for treating wet-age-related macular degeneration. Stock up.